
# VITROS® HIV Combo Test



## You deliver more than results. You deliver trust.

VITROS HIV Combo Test\* provides early detection of acute HIV-1 infection¹ with class-leading² fourth-generation antigen sensitivity combined with uncompromised specificity.



## Earlier detection.<sup>3</sup> Improved diagnosis and prevention.

#### VITROS HIV Combo, a 4th generation test, detects HIV-1 infection earlier than 3rd generation tests.3

In 2014, the Centers for Disease Control and Prevention and the Association for Public Health Laboratories updated recommendations to fourth-generation tests for initial HIV screening.3 Fourth-generation tests simultaneously detect HIV-1 and 2 IgM/IgG antibodies, as well as the p24 antigen. Compared to thirdgeneration HIV tests, which only detect antibodies, p24 antigen detection allows fourth-generation assays to detect an acute HIV infection approximately 7-11 days earlier.<sup>3,4</sup>


- The VITROS HIV Combo Test became reactive earlier for six of 32 seroconversion panels (agreement for 25 of 32 panels) when compared to a leading commercially available fourth-generation Ag/Ab test.5
- Seroconversion panels are a group of serial bleeds from plasma donors during seroconversion. They are intended for use by manufacturers and clinical laboratories to evaluate assay sensitivity.

Seroconversion panel data shows that the VITROS HIV Combo Test delivers even earlier detection than a leading fourthgeneration test.5

### Build trust with performance.

With class-leading<sup>2</sup> antigen sensitivity that doesn't sacrifice specificity, the VITROS HIV Combo Test delivers the utmost confidence in results and can help save cost, time and labor in repeat and confirmatory testing.<sup>3</sup>

- Analytical sensitivity shows a state-ofthe-art<sup>2</sup> limit of 0.46 IU/mL (range 0.45-0.48 IU/mL) NIBSC/WHO and 12.8 pg/mL (range 12.6 - 13.1 pg/mL) AFSSAPS<sup>1</sup>
- Clinical specificity was calculated as 99.58% (CI 99.38%-99.73%) for adult low risk population<sup>1</sup>



Detection of HIV-1 viral nucleic acid with Nucleic Acid Test (NAT) remains the most sensitive method in identifying acute HIV-1 infection but its use is not widespread due to associated cost, time and labor.

AFSSAPS: French Health Products Safety Agency
NIBSC: The National Institute for Biological Standards and Control
WHO: World Health Organization

## A combination you can count on for your patients and your lab.

The performance of the VITROS HIV Combo Test is enhanced by the proprietary technologies and benefits only available on VITROS Systems:



**INTELLICHECK® Technology** monitors, verifies and documents diagnostic checks throughout sample assay processing. This prevents reporting of results that may be affected by exceptions.



**MicroSensor technology** detects endogenous interferences and flags affected results without the use of reagents or extra consumables. This verifies the integrity of the processed sample.



**MicroWell technology** combined with our enhanced chemiluminescence detection technology improves signal detection with outstanding precision and wide dynamic range.



**VersaTip technology** is designed to eliminate sample carryover and cross-contamination using disposable tips (for samples and reagents on VITROS® ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS® 5600/XT 7600 Integrated Systems).



**Operational simplicity** with the ability to load while running and excellent reagent/calibration stability.



**Seamless integration** into VITROS ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS 5600/XT 7600 Integrated Systems.

With the addition of the new VITROS® HIV Combo Controls, we solidify our commitment to help our customers achieve results they can trust and instill confidence in the decisions your clinicians make for the patients you serve.

#### Comprehensive Infectious Disease Immunodiagnostic Menu of Assays

Anti-HIV 1+2

Anti-HBe

Anti-HAV Total

HBsAg Confirmatory

Anti-HCV

Anti-HBs

HBeAg

Rubella IgG

Anti-HBc

Anti-HAV IgM

HBsAg

HIV Combo

Anti-HBc IgM

#### **Ordering Information**

Product Name			Catalog Code
VITROS Immunodiagnostic Products HIV Combo Reagent Pack			684 2781
VITROS Immunodiagnostic Products HIV Combo Calibrator			684 2782
Product Name	Kit Contents	Volume	Catalog Code
VITROS® HIV Combo Controls (Negative, Anti-HIV-1, Anti-HIV-2)	3 sets of ready-to-use tubes - 9 tubes in 1 kit	4 mL in each tube	691 2261
VITROS® HIV Combo Controls (Anti-HIV-1 group 0)	3 ready-to-use tubes in 1 kit	4 mL in each tube	691 2265
VITROS® HIV Combo Controls (HIV p24 Antigen)	9 Glass vials in 1 kit	1.2 mL in each vial	691 2263

**Let's Get Started** Contact your local Ortho Clinical Diagnostics representative to bring the early detection capabilities of the VITROS HIV Combo Test to your lab.

5. Data on file.

© Ortho Clinical Diagnostics 2021. "Because Every Test Is A Life" is a trademark of Ortho Clinical Diagnostics. PR-11830

<sup>1.</sup> VITROS HIV Combo Test Instructions for Use, GEM1256\_US\_EN.

 $<sup>2. \</sup> Based \ on \ NIBSC/AFSSAPS \ standards \ data \ from \ three \ other \ 4th \ generation \ manufacturers' \ assay \ Instructions \ for \ Use.$ 

<sup>3.</sup> Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at http://stacks.cdc.gov/view/cdc/23447. Published June 27, 2014.

<sup>4.</sup> Mitchell E.O., Stewart G, Bajzik O, Ferret M, Bentsen C, Shriver M.K. (2013). Performance comparison of the 4th generation Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA on the EVOLIS™ automated system versus Abbott ARCHITECT HIV Ag/Ab Combo, Ortho Anti-HIV 1+ 2 EIA on VITROS ECi and Siemens HIV-1/0/2 enhanced on Advia Centaur. J Clin Virol. 2013:58:e79-e84